NPY and energy homeostasis: an opportunity for novel anti-obesity therapies.
MacNeil
Douglas J
DJ
Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07090, USA. doug_macneil@merck.com
Kanatani
Akio
A
D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D004734:Energy Metabolism / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D006706:Homeostasis / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D006801:Humans; D009478:Neuropeptide Y / Q000819:agonists / Q000235:genetics / Q000502:physiology*; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism*
D019440:Anti-Obesity Agents; D009478:Neuropeptide Y